Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
To assess the safety of lengthening the adalimumab dosing interval from 2 to 3 weeks, in patients with Crohn's disease or ulcerative colitis in long term (6 months) remission.
Inclusion criteria
- inflammatory bowel disease